@article{22889c199bdc405993823712488105a6,
title = "Management of Parkinson's disease 20 years from now: Towards digital health pathways",
abstract = "Current best medical treatment for patients with Parkinson's disease (PD) involves a medical professional who applies state-of-the-art knowledge of diagnostics and treatment-as derived from cohort studies and clinical trials-to the healthcare process of individual patients. Thus, the much-needed personalization of medicine depends on the abilities, experience and intuition of medical professionals to adjust group-based knowledge to individual decision making.Within 20 years from now, such personal clinical decisions will be largely supported by digital means, also defining a new ecosystem of healthcare often referred to as {"}digital medicine{"}.We expect that the next phase of digitalization will include new{"}digital health pathways{"}: Data-driven personalized decision support that is based on a combination of multimodal data sources, including evidence-based medical knowledge (e.g., clinical guidelines), personal disease profiles (including genetic determinants of disease progression and treatment response), insights into individual disease trajectories (thereby defining subgroups of patients) and individual patients' needs. Here, we illustrate the potential of this development by sketching the contours of a digitally supported care pathway for gait disability and falls. Such digital health pathways will support the introduction of personalized medicine for PD patients, allowing patients to benefit optimally from individually tailored treatments. This should result in a better quality of life for patients and lower costs for society.",
keywords = "Digital pathways, Healthcare, Innovation, Management, Parkinson's disease, Treatment",
author = "Jochen Klucken and Rejko Kruger and Peter Schmidt and Bloem, {Bastiaan R.}",
note = "Funding Information: RK serves as Editorial Board Member of the European Journal of Clinical Investigation, the Journal of Parkinsonism and Related Disorders and the Journal of Neural Transmission. Dr. Kr{\"u}ger has received research grants from Fonds National de Recherche de Luxembourg (FNR; PEARL [FNR/P13/6682797/Kr{\"u}ger], MiRisk [C17/BM/11676395], MotaSYN [12719684], MAMaSyn-PD and NCER-PD), the German Research Council (DFG; KR2119/8-1), the Michael J Fox Foundation, the European Union{\textquoteright}s Joint Program-Neurodegenerative Diseases (JPND; COURAGE-PD), the European Union{\textquoteright}s Horizon2020 research and innovation program (WIDESPREAD; CENTRE-PD; grant agreement no. 692320) and the the Federal Ministry for Education and Research (BMBF; Mito-PD 031 A 430 A), as well as speaker{\textquoteright}s honoraria and/or travel grants from Abbvie, Zambon and Medtronic. Dr Kr{\"u}ger participated as PI or site-PI for industry sponsored clinical trials without receiving honoraria. Funding Information: The manuscript was supported by an EIT- Health grant “MoveIT”. JK was supported by a research grant from the Bavarian Ministry of Economics (FallRiskPD), EIT-Health (MoveIT), EIT-Digital (Vital@Home), and by a Fraunhofer Attract grant (DHPs). RK was supported research grants from Fonds National de Recherche de Luxembourg (FNR; PEARL [FNR/P13/6682797] and NCER-PD [FNR/ NCER13/BM/11264123]), and the European Union{\textquoteright}s Horizon2020 research and innovation program (WIDESPREAD; CENTRE-PD; grant agreement no. 692320; CENTRE-PD). Prof. Bastiaan JK has received institutional research grants from Bavarian Research Foundation; Emerging Field Initiative, FAU; EIT-Health; EIT-Digital; EU (H2020), German Research Foundation (DFG); BMBF. Industry sponsored institutional IITs and grants from Teva GmbH; Licher MT GmbH; Astrum IT GmbH; Alpha-Telemed AG. He works on advisory boards in the field of healthcare technologies and digital health of different associations of medical professionals, industries, and political authorities. He holds shares of Portabiles HealthCare Technologies GmbH, Portabiles GmbH, Alpha-Telemed AG, and received compensation and honoraria from serving on scientific advisory boards for LicherMT GmbH, Abbvie GmbH, UCB Pharma GmbH, Athenion GmbH, and Thomashilfen GmbH; as well as lecturing from UCB Pharma GmbH, TEVA Pharma GmbH, Licher MT GmbH, Desitin GmbH, Abbvie GmbH, Solvay Pharmaceuticals, and Ever Neuro Pharma GmbH; Dr. Klucken has a patent related to gait assessments pending. Funding Information: BB currently serves as Associate Editor for the Journal of Parkinson{\textquoteright}s disease, serves on the editorial of Practical Neurology, has received honoraria from serving on the scientific advisory board for Abbvie, Biogen, UCB and Walk with Path, has received fees for speaking at conferences from AbbVie, Zambon and Bial, and has received research support from the Netherlands Organization for Scientific Research, the Michael J Fox Foundation, UCB, Abbvie, the Sticht-ing Parkinson Fonds, the Hersenstichting Nederland, the Parkinson{\textquoteright}s Foundation, Verily Life Sciences, Horizon 2020, the Topsector Life Sciences and Health, and the Parkinson Vereniging. Funding Information: PS{\textquoteright}s work was supported by the Parkinson{\textquoteright}s Foundation and has received institutional support from the Patient-Centered Outcomes Research Institute, Robert Wood Johnson Foundation, CHDI, and the Cystic Fibrosis Foundation. He serves on the corporate boards of the Huntington{\textquoteright}s Disease Study Group, Davis Phinney Foundation, and Night Nurse Triage. Publisher Copyright: {\textcopyright} 2018 IOS Press and the authors. All rights reserved.",
year = "2018",
doi = "10.3233/JPD-181519",
language = "English",
volume = "8",
pages = "S85--S94",
journal = "Journal of Parkinson's Disease",
issn = "1877-7171",
publisher = "IOS Press BV",
number = "s1",
}